Trials that use: Risk difference
New to this method? Read the tutorial →
6,276 results
- Tailored Approaches to Improve Medication Adherence: Complete Statistical AnalysisIndependent statistical analysis of Tailored Approaches to Improve Medication Adherence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01643473).
- Tailored-AFIndependent statistical analysis of Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04702451).
- Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV: Complete Statistical AnalysisIndependent statistical analysis of Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Tailoring Treatment Targets for Early Autism Intervention in Africa: Complete Statistical AnalysisIndependent statistical analysis of Tailoring Treatment Targets for Early Autism Intervention in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04068688).
- TAK-114 Single- and Multiple-Dose Phase 1 Study: Complete Statistical AnalysisIndependent statistical analysis of TAK-114 Single- and Multiple-Dose Phase 1 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02286518).
- TALAPRO-2Independent statistical analysis of Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395197).
- Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TANDEMIndependent statistical analysis of Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis: primary endpoint results, effect estimate with…
- Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment: Complete Statistical AnalysisIndependent statistical analysis of Tandem Auto Transplantation in Myeloma Patients With
- TANGOIndependent statistical analysis of A Phase 3 Study of Tanezumab for Chronic Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- TAPIndependent statistical analysis of Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TAP HYSIndependent statistical analysis of Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01074229).
- TAPASIndependent statistical analysis of TissuePAtchDS--P ™ PArotidectomy Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04116762).
- TAPERIndependent statistical analysis of Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal: primary endpoint results, effect estimate with confidence interval,…
- TARGETIndependent statistical analysis of Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TARGETIndependent statistical analysis of Role of On-site CT-derived FFR in the Management of Suspect CAD Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: Complete Statistical AnalysisIndependent statistical analysis of Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Targeting IL-17A for Treatment-Resistant Depression: Complete Statistical AnalysisIndependent statistical analysis of Targeting IL-17A for Treatment-Resistant Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04979910).
- TARMICIndependent statistical analysis of Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TAS3351Independent statistical analysis of A Study of TAS3351 in NSCLC Patients With EGFRmt: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05765734).
- TASCIndependent statistical analysis of Aortoiliac Stenosis in Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06020534).
- TASCIndependent statistical analysis of Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00524771).
- TASTERIndependent statistical analysis of Ticagrelor Administered as Standard Tablet or Orodispersible Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03822377).
- TAXYNERGYIndependent statistical analysis of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with…
- TBKT_HEPIndependent statistical analysis of Thera-Band® HEP for LBP Secondary Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02355275).
- TCM-700CIndependent statistical analysis of The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- TD-0903 for ALI Associated With COVID-19: Complete Statistical AnalysisIndependent statistical analysis of TD-0903 for ALI Associated With COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04402866).
- Tdap Vaccine Safety for Plasma Donors: Complete Statistical AnalysisIndependent statistical analysis of Tdap Vaccine Safety for Plasma Donors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04142983).
- TEACOIndependent statistical analysis of TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00296816).
- TEAMIndependent statistical analysis of A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TECH-EIndependent statistical analysis of Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Technology Enhanced Family Treatment: Complete Statistical AnalysisIndependent statistical analysis of Technology Enhanced Family Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03913013).
- TECTONICSIndependent statistical analysis of Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TeenCoveComplete statistical analysis of the TeenCove trial of mRNA-1273 and mRNA-1273.222 in adolescents 12 to
- Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies: Complete Statistical AnalysisIndependent statistical analysis of Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142298).
- TELE001Independent statistical analysis of Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF): Complete Statistical AnalysisIndependent statistical analysis of Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03562247).
- Telephone-linked Home-based Exercise Training in PD: Complete Statistical AnalysisIndependent statistical analysis of Telephone-linked Home-based Exercise Training in PD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02898740).
- Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2): Complete Statistical AnalysisIndependent statistical analysis of Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00723827).
- Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00026494).
- Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy – Observational Program (Study P04816): Complete Statistical AnalysisIndependent statistical analysis of Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Temozolomide in Treating Patients With Low-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide in Treating Patients With Low-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00313729).
- Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…